Klutmann S, Bohuslavizki K H, Brenner W, Behnke A, Tietje N, Kröger S, Hugo H H, Mehdorn H M, Clausen M, Henze E
Clinic of Nuclear Medicine, Christian-Albrechts-University of Kiel, Germany.
J Nucl Med. 1998 Nov;39(11):1913-7.
Surgery is the treatment of choice in patients with meningioma. However, the risk of postoperative, local recurrence is well-known since total resection is not always feasible. Moreover, in these patients MRI may fail to differentiate between tumor remnants, recurrent meningioma or nonspecific hyperperfusion. In this study, the value of functional imaging using somatostatin receptor scintigraphy (SRS) was evaluated in postsurgical follow-up.
Before and 2-3 mo after surgery, 27 patients with meningioma received MRI as well as SRS after intravenous injection of 200 MBq 111In-octreotide. Planar whole-body images were obtained at 10 min, 1, 4 and 24 hr postinjection, and SPECT was performed at 4 and 24 hr postinjection. The final diagnosis was proven histologically in all patients.
Before surgery, MRI showed focal contrast enhancement in all patients, and SRS revealed focal accumulation of 111In-octreotide. Thus, MRI and SRS yielded comparable results in all 27 patients. After surgery, MRI showed diffuse contrast enhancement in the area of the primary tumor site in all patients. Thus, MRI did not allow a differentiation between tumor and nonspecific hyperperfusion. In contrast, SRS revealed focal accumulation of 111In-octreotide in 16 of 27 patients indicating remaining tumor tissue or relapse of meningioma. This resulted either in an operative revision or in more frequent postsurgical follow-up examinations. In 11 of 27 patients, SRS was negative. Thus, total resection of meningioma was assumed, and no further interventions were performed.
Functional imaging using SRS is a highly specific imaging modality and has a significant impact in postsurgical follow-up in patients with meningioma.
手术是脑膜瘤患者的首选治疗方法。然而,由于并非总能实现全切除,术后局部复发的风险是众所周知的。此外,在这些患者中,MRI可能无法区分肿瘤残留、复发性脑膜瘤或非特异性高灌注。在本研究中,评估了使用生长抑素受体闪烁显像(SRS)进行功能成像在术后随访中的价值。
27例脑膜瘤患者在手术前及术后2 - 3个月,静脉注射200MBq 111In - 奥曲肽后接受MRI及SRS检查。在注射后10分钟、1小时、4小时和24小时获取平面全身图像,并在注射后4小时和24小时进行SPECT检查。所有患者的最终诊断均经组织学证实。
手术前,MRI显示所有患者均有局灶性对比增强,SRS显示111In - 奥曲肽局灶性聚集。因此,MRI和SRS在所有27例患者中得出了可比的结果。手术后,MRI显示所有患者原发肿瘤部位区域有弥漫性对比增强。因此,MRI无法区分肿瘤与非特异性高灌注。相比之下,SRS显示27例患者中有16例111In - 奥曲肽局灶性聚集,提示存在残留肿瘤组织或脑膜瘤复发。这导致了手术修正或更频繁的术后随访检查。27例患者中有11例SRS为阴性。因此,假定脑膜瘤已全切除,未进行进一步干预。
使用SRS进行功能成像是一种高度特异性的成像方式,对脑膜瘤患者的术后随访有重大影响。